Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
Madrigal Pharmaceuticals announced the issuance of three new U.S. patents for Rezdiffra (resmetirom), covering dosing methods for F2/F3 MASH and a new indication for well-compensated cirrhosis. The patents extend intellectual property protection to 2045 for F2/F3 dosing with CYP2C8 inhibitors and to 2042 for the F4c indication and co-administration with rosuvastatin.
Key figures
- Drug Name
- Rezdiffra (resmetirom)
- Patent numbers
- ["12,667,575","12,661,359","12,661,361"]
- F4c protection year
- 2042
- F2 f3 protection year
- 2045
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.